Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries

ClinicalTrials.gov ID: NCT03927911

Public ClinicalTrials.gov record NCT03927911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Prospective, Active Controlled, Real World, Phase 4 Study of EXPAREL in Multimodal Regimens Compared With Standard of Care for Postsurgical Pain Management in Subjects Undergoing Lumbar Posterior Spine Surgeries (FUSION)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary Objective: The primary objective of this study is to compare postsurgical opioid consumption through 72 hours postsurgery in patients receiving local infiltration analgesia (LIA) with EXPAREL and bupivacaine HCl (EXPAREL group) with that of patients receiving standard of care (SOC) (control group) in adult subjects undergoing posterior lumbar spine surgeries where both groups are receiving a multimodal pain regimen. Secondary Objectives: The secondary objectives of this study are to: 1. Compare safety and effectiveness outcomes following LIA with EXPAREL and bupivacaine hydrochloride (HCl) versus SOC in adult subjects undergoing posterior lumbar spine surgeries through 72 hours, including time to first opioid and opioid-related adverse events (ORAEs). 2. Compare health outcomes following LIA with EXPAREL and bupivacaine hydrochloride (HCl) versus SOC in adult subjects undergoing posterior lumbar spine surgeries, including discharge readiness, hospital (or other facility) length of stay (LOS), discharge disposition, hospital readmissions, and health service utilization.

Study identification

NCT ID
NCT03927911
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Enrollment
65 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 30, 2019
Primary completion
Aug 3, 2020
Completion
Aug 3, 2020
Last update posted
Nov 8, 2021

2019 – 2020

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
Yale School of Medicine New Haven Connecticut 06511
Marcus Neuroscience Institute Boca Raton Florida 33486
University of Miami Miami Florida 33136
NorthShore University HealthSystem Evanston Illinois 60201
The Orthopaedic Institute of Western Kentucky Paducah Kentucky 42003
Bronson Methodist Hospital Kalamazoo Michigan 49007
Mayo Clinic Rochester Minnesota 55905
Carolina NeuroSurgery & Spine Associates, P.A. Charlotte North Carolina 28204
M3-Emerging Medical Research, LLC Durham North Carolina 27704
The Ohio State University Columbus Ohio 43203
Summit Spine Institute Portland Oregon 97225
First Surgical Hospital Bellaire Texas 77401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03927911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03927911 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →